Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma.

doi:10.1016/j.ccell.2026.03.020

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma.

Cancer cell - 8 Jun 2026

Entrialgo-Cadierno Rodrigo, Morali Konstantina, Feliu Iker, Wang Yingyun, Evans James W, Yañez-Bartolome Mariana, Lopez Ines, Macaya Irati, Cueto-Ureña Cristina, Sin-Coscujuela Daniel, Senent Yaiza, Herranz Jose M, Raghulan Rashi, Vaquero Javier, Banales Jesus M, Macarulla Teresa, Ponz-Sarvise Mariano, Pechuan-Jorge Ximo, Guruceaga Elisabeth, Schumpp Alyssa, Garcia Alia V, Kim Alyssa, Herzberg Benjamin O, Azad Nilofer, Hegde Aparna, Tian Tian V, Aronchik Ida, Singh Mallika, Jiang Jingjing, Vicent Silve

Abstract excerpt

About 25% of cholangiocarcinoma (CCA) tumors harbor KRAS mutations. Here, we investigated the activity of RAS(ON) multi-selective inhibitors, which target the active, GTP-bound state of mutant and wild-type variants of canonical RAS isoforms, in preclinical models and in patients with KRAS mutant CCA. RAS(ON) multi-selective inhibitors yield strong anticancer responses in cell- and patient-derived xenografts and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cholangiocarcinoma

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Bile Duct Neoplasms

Share to Guanosine Triphosphate

Share to Piperazines

Share to Proto-Oncogene Proteins p21(ras)

Share to Pyrimidines

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed

Identifiers

PMID: 42030930
DOI: 10.1016/j.ccell.2026.03.020

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma.PMID 42030930Read ↗

RAS-ing the bar in the treatment of KRAS-mutant cholangiocarcinoma.Semantic proximity Read ↗

Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers.Semantic proximity Read ↗

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.Semantic proximity Read ↗

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapySemantic proximity Read ↗

Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistanceSemantic proximity Read ↗

A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer.Semantic proximity Read ↗

The evolving role of futibatinib for advanced cholangiocarcinoma.Semantic proximity Read ↗

FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma.Semantic proximity Read ↗

Finding the sweet spot: Targeting RAS in tumors while sparing normal tissue.Semantic proximity Read ↗

Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants.Semantic proximity Read ↗

FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements.Semantic proximity Read ↗

RAS-GTP Inhibition Overcomes Acquired Resistance to KRASG12C Inhibitors Mediated by Oncogenic and Wild-Type RAS Activation in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.